Science & Enterprise subscription

Follow us on Twitter

  • When even PhRMA doesn't want to be a Trump campaign prop ... A Deal on Drug Prices Undone by White House Insistence… https://t.co/JjdVxOTVV6
    about 13 hours ago
  • A company developing a drug for depression based on synthesized compounds in hallucinogenic substances is raising $… https://t.co/D8kwt0ng5X
    about 14 hours ago
  • New post on Science and Enterprise: Mental Health Drug Company Raises $127.5M in IPO https://t.co/39Xea7VQpV #Science #Business
    about 14 hours ago
  • A test for SARS-CoV-2 viruses is shown in field tests to return diagnostic results in 90 minutes with accuracy comp… https://t.co/EuQIPTsL57
    about 17 hours ago
  • New post on Science and Enterprise: Point-of-Care Covid-19 Diagnostic Shows High Accuracy https://t.co/4l3pGrHx2o #Science #Business
    about 17 hours ago

Please share Science & Enterprise

GSK, Johnson & Johnson Join in Life Science Venture Fund

Euro Notes and Coins (U.S. Mint)

(U.S. Mint)

The London-based venture capital company Index Ventures unveiled a new investment fund for early-stage life sciences companies, with pharmaceutical companies GlaxoSmithKline and Janssen, a division of Johnson & Johnson, among the investors. The Index Life VI fund, valued at €150 million ($US230 million), is the first for Index Ventures devoted solely to the life sciences.

The company says the fund is aimed at promising early-stage enterprises with one or two projects, rather than firms with multiple undertakings. New companies in Europe will be considered first for support, but also those in the U.S. that have first-in-class or best-in-class solutions addressing unmet medical needs.

Index Ventures says it will form an advisory board with representatives from GlaxoSmithKline and Janssen, as well as five other executives appointed by the company, to assess potential investment opportunities. The company aims to advise and support its portfolio companies rather than taking an ownership position. In some cases, Index Ventures will offer its facilities as an incubator for start-ups.

While this fund is the first Index Ventures vehicle focusing only on life sciences, the company has previously backed biotechnology and pharmaceutical enterprises in other funds. In start-up rounds, Index Ventures has invested in Genmab A/S, PanGenetics B/V, Aegerion Inc., Addex Pharmaceuticals Ltd., ParAllele BioScience Inc., Molecular Partners AG, and ProFibrix BV. In later-stage rounds, Index Ventures has supported Micromet and Ariad, Inc.

Read more:

*     *     *

2 comments to GSK, Johnson & Johnson Join in Life Science Venture Fund